Malignant melanoma in elderly patients: biological, surgical and medical issues

References

• Malaguarnera G, Giordano M, Cappellani A, et al. Skin cancers in elderly patients. Anticancer Agents Med Chem 2013;13(9):1406-11
   PubMedGoogle Scholar
• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445(7130):851-7
   PubMed Web of Science ®Google Scholar
• Miller AJ, Mihm MCJr. Melanoma. N Engl J Med 2006;355(1):51-65
   PubMed Web of Science ®Google Scholar
• MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Onco 2009;20(Suppl 6):vi1-7
   PubMed Web of Science ®Google Scholar
• Tsai S, Balch C, Lange J. Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol 2010;7(3):148-52
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics.2014. CA Cancer. J Clin 2014;64(1):9-29
   Google Scholar
• Department of Economic and Social Affairs Population Division. World population prospects the 2006 revision highlights. United Nations Publications; New York, NY, USA: 2007
   Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France; 2013. Available from: http://globocan.iarc.fr [Last accessed 11 May 2014]
   Google Scholar
• Thomas NE, Berwick M, Cordeiro-Stone M. Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 2006;126(8):1693-6
   PubMedGoogle Scholar
• Libra M, Malaponte G, Navolanic PM, et al. Analysis of. BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005;4(10):382-1384
   Google Scholar
• Cardile V, Malaponte G, Loreto C, et al. Raf kinase inhibitor protein (RKIP) and phospho-RKIP expression in melanomas. Acta Histochem 2013;115(8):795-802
   PubMedGoogle Scholar
• Maira F, Catania A, Candido S, et al. Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. Curr Drug Deliv 2012;9(1):7-29
   Google Scholar
• Russo AE, Torrisi E, Bevelacqua Y, et al. Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 2009;34(6):1481-9
   PubMed Web of Science ®Google Scholar
• Candido S, Rapisarda V, Marconi A, et al. Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure. Oncol Rep 2014;31(3):1079-82
   PubMedGoogle Scholar
• Seidler AM, Pennie ML, Veledar E, et al. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Arch Dermatol 2010;146(3):249-56
   PubMedGoogle Scholar
• Caraco C, Marone U, Botti G, et al. Age as predictor in patients with cutaneous melanoma submitted to sentinel lymph node biopsy. Eur J Surg Oncol 2006;32(9):970-3
   PubMedGoogle Scholar
• Pennie ML, Soon SL, Risser JB, et al. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a non dermatologist. Arch Dermatol 2007;143(4):488-94
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19(16):3622-34
   PubMed Web of Science ®Google Scholar
• Ciocan D, Barbe C, Aubin F, et al. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol 2013;149(10):1150-7
   PubMed Web of Science ®Google Scholar
• Geller AC, Sober AJ, Zhang Z, et al. Strategies for improving melanoma education and screening for men age >or= 50 years: findings from the American Academy of Dermatological National Skin Cancer Screening Program. Cancer 2002;95(7):1554-61
   PubMedGoogle Scholar
• Martinez SR, Shah DR, Yang AD, et al. Sentinel lymph node biopsy in patients with thick primary cutaneous melanoma: patterns of use and underuse utilizing a population-based model. ISRN Dermatol 2013;2013:315609
   PubMedGoogle Scholar
• Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol 2008;15(6):1566-76
   PubMed Web of Science ®Google Scholar
• Shah DR, Yang AD, Maverakis E, Martinez SR. Age-related disparities in use of completion lymphadenectomy for melanoma sentinel lymph node metastasis. J Surg Res 2013;185(1):240-4
   PubMedGoogle Scholar
• Hegde UP, Grant-Kels JM. Metastatic melanoma in the older patient: special considerations. Clin Dermatol 2013;31(3):311-16
   PubMed Web of Science ®Google Scholar
• Malaguarnera L, Ferlito L, Di Mauro S, et al. Immunosenescence and cancer: a review. Arch Gerontol Geriatr 2001;32(2):77-93
   PubMed Web of Science ®Google Scholar
• Malaguarnera L, Cristaldi E, Malaguarnera M. The role of immunity in elderly cancer. Crit Rev Oncol Hematol 2010;74(1):40-60
   PubMedGoogle Scholar
• Malaguarnera M, Cristaldi E, Romano G, Malaguarnera L. Autoimmunity in the elderly: implications for cancer. J Cancer Res Ther 2012;8(4):520-7
   PubMedGoogle Scholar
• Motta M, Ferlito L, Malaguarnera L, et al. Alterations of the lymphocytic set-up in elderly patients with cancer. Arch Gerontol Geriatr 2003;36(1):7-14
   PubMedGoogle Scholar
• Spaulding C, Guo W, Effros RB. Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol 1999;34(5):633-44
   PubMedGoogle Scholar
• Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22(20):3138-51
   PubMed Web of Science ®Google Scholar
• Mukherji B. Immunology of melanoma. Clin Dermatol 2013;31(2):156-65
   PubMed Web of Science ®Google Scholar
• Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer. Immun Ageing 2008;5:11
   PubMedGoogle Scholar
• Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des 2013;19(9):1680-98
   PubMed Web of Science ®Google Scholar
• Van der Meijden WA, van Bruchem-Visser RL, Thio HB, van der Cammen TJ. Melanomas more serious in the elderly. Ned Tijdschr Geneeskd 2010;154:A1535
   PubMedGoogle Scholar
• Clark JM, Kelley B, Titze J, et al. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Oncology 2013;84:123-6
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Wandert T, Reitz M. Age does not impair the efficacy of immunotherapy in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2005;55(3):193-9
   PubMedGoogle Scholar
• Quan WJr, Ramirez M, Taylor C, et al. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over. Cancer Biother. Radiopharm 2005;20(1):11-15
   Google Scholar
• Tagawa ST, Cheung E, Banta W, et al. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. Cancer 2006;106(6):1353-7
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23(35):8968-77
   PubMed Web of Science ®Google Scholar
• Pawelec G, Solana R, Remarque E, Mariani E. Impact of aging on innate immunity. J Leukoc Biol 1998;64(6):703-12
   PubMedGoogle Scholar
• Salminen A, Huuskonen J, Ojala J, et al. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev 2008;7(2):83-105
   PubMed Web of Science ®Google Scholar
• Hegde UP, Chakraborty N, Kerr P, Grant-Kels JM. Melanoma in the elderly patient: relevance of the aging immune system. Clin Dermatol 2009;27(6):537-44
   PubMedGoogle Scholar
• Hegde UP, Chhabra A, Chakraborty NG. Lack of T reg cell function and melanoma tumor antigen-specific responses in some elderly patients. [Abstract 248]. Presented at 99th Annual Meeting of American Association of Cancer Research; 12 − 16 April 2008; San Diego, CA, USA
   Google Scholar
• Hegde UP, Chakraborty N, Mukherji B, Grant Kels JM. Metastatic melanoma in the older patient: immunologic insights and treatment outcomes. Expert Rev Pharmacoecon Outcomes Res 2011;11(2):185-93
   PubMed Web of Science ®Google Scholar
• Cohen HJ, Cox E, Manton K, Woodbury M. Malignant melanoma in the elderly. J Clin Oncol 1987;5(1):100-6
   PubMed Web of Science ®Google Scholar
• Averbook BJ, Russo LJ, Mansour EG. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 1998;124(4):746-56
   PubMedGoogle Scholar
• MacKie RM. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol 2000;25(6):471-5
   PubMedGoogle Scholar
• Ramesh HS, Pope D, Gennari R, Audisio RA. Optimising surgical management of elderly cancer patients. World J Surg Oncol 2005;3:17
   PubMedGoogle Scholar
• Kelly JW. Melanoma in the elderly a neglected public health challenge. Med J Aust 1998;169(8):403-4
   PubMedGoogle Scholar
• Lasithiotakis KG, Petrakis IE, Garbe C. Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res 2010;20(3):163-70
   PubMedGoogle Scholar
• Hanrahan PF, Hersey P, D’Este CA. Factors involved in presentation of older people with thick melanoma. Med J Aust 1998;169(8):410-14
   PubMedGoogle Scholar
• Kallini JR, Jain SK, Khachemoune A. Lentigo maligna: review of salient characteristics and management. Am J Clin Dermatol 2013;14(6):473-80
   PubMed Web of Science ®Google Scholar
• Perrotta R, Bevelacqua Y, Malaguarnera G, et al. Serum markers of cutaneous melanoma. Front Biosci (Elite Ed) 2010;2:1115-22
   PubMedGoogle Scholar
• Malaponte G, Zacchia A, Bevelacqua Y, et al. Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression. Oncol Rep 2010;24(1):81-7
   PubMedGoogle Scholar
• Houghton A, Coit D, Bloomer W, et al. NCCN melanoma practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park) 1998;12(7A):153-77
   PubMedGoogle Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• Covarelli P, Vedovati MC, Becattini C, et al. The sentinel node biopsy in patients with thick melanoma: outcome analysis from a single-institution database. In Vivo 2011;25(3):439-43
   PubMedGoogle Scholar
• Ferrone CR, Panageas KS, Busam K, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002;9(7):637-45
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000;7(2):160-5
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 2008;6(3):198-203
   PubMed Web of Science ®Google Scholar
• Jacobs IA, Chang CK, Salti GI. Role of sentinel lymph node biopsy in patients with thick (>4mm) primary melanoma. Am Surg 2004;70(1):59-62
   PubMedGoogle Scholar
• Ra JH, McMasters KM, Spitz FR. Should all melanoma patients undergo sentinel lymph node biopsy? Curr Opin Oncol 2006;18(2):185-8
   PubMedGoogle Scholar
• Rondelli F, Vedovati MC, Becattini C, et al. Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta-analysis. J Eur Acad Dermatol Venereol 2012;26(5):560-5
   PubMedGoogle Scholar
• Vermeeren L, van der Ent FW, Sastrowijoto PS, Hulsewé KW. Thick melanoma: prognostic value of positive sentinel nodes. World J Surg 2009;33(11):2464-8
   PubMedGoogle Scholar
• Essner R, Chung MH, Bleicher R, et al. Prognostic implications of thick (≥4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 2002;9(8):754-61
   PubMedGoogle Scholar
• Chao C, Martin RCII, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004;11(3):259-64
   PubMed Web of Science ®Google Scholar
• Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11(3):247-58
   PubMed Web of Science ®Google Scholar
• Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003;21(7):1326-31
   PubMed Web of Science ®Google Scholar
• Fenske NA, Lober CW. Structural and functional changes of normal aging skin. J Am Acad Dermatol 1986;15(4 Pt 1):571-85
   PubMed Web of Science ®Google Scholar
• Luscieti P, Hubschmid T, Cottier H, et al. Human lymph node morphology as a function of age and site. J Clin Pathol 1980;33(5):454-61
   PubMed Web of Science ®Google Scholar
• Conway WC, Faries MB, Nicholl MB, et al. Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol 2009;16(6):1548-52
   PubMedGoogle Scholar
• Sassen S, Shaw HM, Colman MH, et al. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center. Ann Surg Oncol 2008;15(2):630-7
   PubMedGoogle Scholar
• Guggenheim MM, Hug U, Jung FJ, et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg 2008;247(4):687-93
   PubMedGoogle Scholar
• Kingham TP, Panageas KS, Ariyan CE, et al. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol 2010;17(2):514-20
   PubMedGoogle Scholar
• Leong SP. Role of selective sentinel lymph node dissection in head and neck melanoma. J Surg Oncol 2011;104(4):361-8
   PubMedGoogle Scholar
• Willis AI, Ridge JA. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. Head Neck 2007;29(11):979-85
   PubMedGoogle Scholar
• MSLT-II. Complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastases who have undergone sentinel lymphadenectomy (MSLT-ii). Available from: www.clinicaltrials.gov/ct/show/nct00389571?order=1
   Google Scholar
• Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol 2006;155(4):771-7
   PubMedGoogle Scholar
• Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006;24(19):3172-7
   PubMedGoogle Scholar
• Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27(1):3-9
   PubMed Web of Science ®Google Scholar
• Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003;46(6):419-26
   PubMedGoogle Scholar
• Albertini JG, Countryman NB. Practice gaps: delayed treatment and inadequate surgical margins for invasive melanoma in elderly patients. JAMA Dermatol 2013;149(10):1158
   PubMedGoogle Scholar
• Livingstone E, Windemuth-Kieselbach C, Eigentler TK, et al. A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. Eur J Cancer 2011;47(13):1977-89
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Wolf J, Harris R, Ferris LK. Screening for Melanoma in Aging Patients. Cutis 2013;91:81-6
   PubMedGoogle Scholar